ALNY SEC Filings

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K on July 30, 2026, primarily to announce its financial results for the second quarter ended June 30, 2026. While the filing itself does not contain the detailed financial figures, it directs investors to an accompanying press release (Exhibit 99.1) for the full earnings announcement. Investors should refer to this press release for critical information regarding the company's performance, revenue, profitability, and any forward-looking guidance.

Alnylam Pharmaceuticals, Inc. reported strong financial performance for the six months ended June 30, 2026, driven by significant growth in net product revenues, primarily from AMVUTTRA. The company achieved a substantial increase in net product revenues, up 94% year-over-year, reaching $2.21 billion, with AMVUTTRA sales more than doubling to $1.90 billion. This growth is largely attributed to the expansion of AMVUTTRA for ATTR-CM in the US and other global markets. While net revenues from collaborations decreased by 20%, this was primarily due to the completion of certain collaboration activities and the wind-down of research terms, partially offset by increased revenue from the Roche collaboration. The company reported a net income of $370.5 million for the six-month period, a significant improvement from a net loss of $90.5 million in the prior year, indicating a strong shift towards profitability. The balance sheet shows healthy liquidity with $1.71 billion in cash and cash equivalents and $1.60 billion in marketable debt securities.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report detailing key governance and shareholder decisions made at its recent Annual Meeting and a board expansion. The company has appointed Dr. Benjamin F. Cravatt to its Board of Directors as a Class III director, effective June 1, 2026, filling a newly created vacancy and also serving on the Science and Technology Committee. This appointment is accompanied by a standard non-employee director compensation package, including an annual cash retainer and initial and ongoing equity awards, designed to align director interests with shareholders. Furthermore, the filing provides an update on the outcomes of the Annual Meeting, including the re-election of three Class I directors, a strong advisory vote of approval for executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026. These events reflect the company's commitment to robust corporate governance and shareholder engagement.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on April 30, 2026, to disclose its financial results for the first quarter ended March 31, 2026. While the report itself provides minimal operational detail, it serves as an official notification that the company has issued a press release containing its quarterly financial performance. Investors should refer to Exhibit 99.1, the furnished press release, for the specific financial data and operational updates for the period. This filing indicates that Alnylam is adhering to its reporting schedule and providing investors with timely, albeit summarized, financial information through an accompanying press release. The key takeaway for investors is to access and review the press release (Exhibit 99.1) for comprehensive details regarding Alnylam's Q1 2026 performance. This includes revenue figures, profitability, any significant developments in its drug pipeline, and forward-looking guidance. The 8-K filing serves as the formal channel for this information, emphasizing the importance of consulting the supplementary materials provided for a complete understanding of the company's financial health and strategic progress.

Alnylam Pharmaceuticals, Inc. demonstrated significant financial performance in the first quarter of 2026, reporting a substantial increase in total revenues to $1.17 billion, primarily driven by a robust surge in net product revenues, which grew by 121% to $1.04 billion. This growth was largely attributed to AMVUTTRA, which saw a remarkable 187% increase in total net product revenues, notably in the U.S. for ATTR-CM treatment. Despite a rise in operating costs and expenses, which increased by 56% to $898.5 million, the company achieved a strong income from operations of $268.6 million, a significant improvement from the prior year's quarter. The company's balance sheet shows a healthy liquidity position with $1.71 billion in cash and cash equivalents. However, the increased interest expense due to liabilities related to the sale of future royalties and development funding, coupled with ongoing significant investments in research and development, indicates a continued focus on pipeline expansion. Management believes existing resources are sufficient for at least the next 12 months, but future capital needs may arise for continued commercialization and pipeline advancement.

Alnylam Pharmaceuticals, Inc. announced on March 4, 2026, the grant of a significant special equity award to its CEO, Yvonne Greenstreet, M.D., M.B.A. This award, effective March 2, 2026, is designed to retain and incentivize Dr. Greenstreet over the next several years, aligning her compensation with substantial future stock price appreciation. The Board recognizes her critical role in the company's recent successes, including nearly 100% stockholder return, key product launches like AMVUTTRA, and the achievement of the 'Alnylam P5x25' goals, including profitability in 2025. The special award is entirely performance-based, with vesting contingent upon the company's stock price reaching specific, ambitious thresholds by December 31, 2029. The award has a target value of $18.0 million, represented by 55,373 performance share units. The terms stipulate that 50% of the target shares vest if the average stock price reaches $500, and 200% vest if it reaches $800, with linear interpolation for performance in between. Importantly, no shares will vest if the stock price does not reach a baseline threshold of $500, which is above the all-time high at the grant date. This structure strongly links executive compensation to significant long-term value creation for shareholders.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 12, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily serves as a vehicle to furnish the accompanying press release containing detailed financial and operational performance information. Investors should refer to Exhibit 99.1, the press release itself, for the substantive details of these results, as this 8-K filing does not contain the specific figures but rather points to the document where they can be found. The company is utilizing this filing to meet its disclosure obligations regarding material events, specifically the release of its earnings. While the 8-K itself is brief, the furnished press release (Exhibit 99.1) is expected to contain crucial information regarding Alnylam's revenue performance, profitability, key product sales (such as ONPZEO, GIVLAARI, and OXLUMO), pipeline advancements, and any forward-looking guidance for the upcoming fiscal year. Investors will be keen to understand the company's financial health, operational execution, and strategic direction as outlined in the earnings announcement. It is imperative for stakeholders to review the content of the press release for a comprehensive understanding of Alnylam's recent performance and future outlook.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed its 10-K for the fiscal year ending on December 31, 2025, highlighting a robust portfolio of six approved RNAi therapeutics and a promising clinical pipeline. The company is executing its "Alnylam 2030" strategy, aiming for significant revenue growth and expansion into new therapeutic areas and tissue types. Key advancements include the recent approvals and ongoing launches of AMVUTTRA for ATTR amyloidosis with cardiomyopathy, and Qfitlia for hemophilia. The company also reported positive clinical trial data for nucresiran, a next-generation ATTR therapy, and zilebesiran for hypertension, underscoring its commitment to innovation and continued pipeline progression. Financially, Alnylam has managed its capital structure by issuing convertible notes and repurchasing existing ones, while also establishing a significant revolving credit facility to support ongoing operations and growth. The company's focus on genetically validated targets and advanced delivery technologies, such as GalNAc conjugates and C16 moieties, positions it to address a wide range of diseases with high unmet needs. Investors should monitor the continued commercial success of its approved products, progress in late-stage clinical trials, and the strategic expansion into prevalent diseases.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K to announce its new five-year strategic plan, "Alnylam 2030." This plan outlines the company's vision and direction for the next five years, aiming to drive growth and innovation in the RNAi therapeutics space. In conjunction with the strategy, Alnylam provided preliminary unaudited financial results for the fourth quarter and full year 2025. The company anticipates approximately $995 million in global net product revenues for Q4 2025 and $2,987 million for the full year 2025, driven by its key products AMVUTTRA®, ONPATTRO®, GIVLAARI®, and OXLUMO®. Alnylam also offered initial product and pipeline goals for 2026, including combined net product revenue guidance.

Alnylam Pharmaceuticals, Inc. (ALNY) announced on December 11, 2025, that it has entered into agreements to repurchase approximately $34.4 million in aggregate principal amount of its 1.00% convertible senior notes due 2027. The total cost for this repurchase is approximately $51.9 million, including accrued interest. This action is expected to reduce the outstanding principal amount of these notes to approximately $362.8 million upon closing. This move suggests Alnylam is actively managing its debt obligations and capital structure. While the financial impact on the company's balance sheet and cash flow will be immediate, the forward-looking statements indicate potential risks related to execution of their strategy, drug development, regulatory approvals, and market performance. Investors should monitor the company's cash position and ongoing debt management strategies.

Alnylam Pharmaceuticals, Inc. (ALNY) announced a change in its Board of Directors composition via an 8-K filing. Michael W. Bonney and Carolyn Bertozzi, Ph.D. have resigned from the Board, effective December 2, 2025. The company explicitly states that these resignations were not due to any disagreements with the company's operations, policies, or practices. Following these departures, the Board size has been reduced from eleven to ten directors. To fill the vacancy and add expertise, the Board has elected Stuart A. Arbuckle as a non-employee director, effective January 5, 2026. Mr. Arbuckle's appointment is accompanied by details of his compensation, which includes an annual cash retainer, an initial stock option grant with a significant fair value, and eligibility for future annual equity awards. This move aims to strengthen the Board's governance and strategic oversight as Alnylam continues its operations.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed a Current Report on Form 8-K to announce its financial results for the quarter ended September 30, 2025. The report primarily serves as a vehicle to furnish the accompanying press release, which contains the detailed financial outcomes for the period. Investors should refer to the press release (Exhibit 99.1) for the specific revenue, earnings, and other key financial metrics. While this 8-K filing itself does not contain the detailed financial data, it signifies the official public disclosure of Alnylam's performance for the third quarter of 2025. The company's forward-looking statements within the press release, if any, would be crucial for assessing future prospects, but are not directly presented in the 8-K filing's core text. Investors are encouraged to review the furnished press release for a comprehensive understanding of the company's operational and financial standing as of and for the quarter ended September 30, 2025.

Alnylam Pharmaceuticals, Inc. (ALNY) reported a strong third quarter of 2025, showcasing significant revenue growth driven by its TTR franchise, particularly AMVUTTRA, and substantial increases in collaboration revenues, largely due to a significant milestone payment from Roche for the zilebesiran program. Total revenues more than doubled year-over-year for both the quarter and the nine-month period, indicating robust commercial execution and successful strategic partnerships. The company demonstrated substantial progress in its financial position, with a significant increase in cash and cash equivalents, largely due to proceeds from the issuance of new convertible senior notes and strong operating cash flow. Despite increased operating costs and expenses, including higher R&D and SG&A spending to support pipeline advancement and commercial expansion, Alnylam achieved operating income and net income for the quarter, a notable improvement from the prior year's loss. The company also strategically managed its debt by repurchasing a portion of its 2027 convertible notes and issuing new 2028 notes, alongside establishing a new revolving credit facility, enhancing its financial flexibility. Key developments in the pipeline include positive results and initiation of Phase 3 trials for nucresiran and zilebesiran, respectively, alongside continued progress in other key programs. The company's commercial products, particularly AMVUTTRA, are showing strong growth, and collaborations with partners like Roche and Regeneron are contributing significantly to revenue, underscoring Alnylam's strategy of building a multi-product, global biopharmaceutical company.

Alnylam Pharmaceuticals, Inc. (ALNY) has announced the execution of a new Credit Agreement, establishing a $500.0 million revolving line of credit set to mature on September 30, 2030. This facility, with a $150.0 million letter of credit sublimit, is intended to support working capital and general corporate purposes. The agreement allows for potential incremental borrowings, subject to customary conditions, and provides flexibility in interest rate options including base rate, Term SOFR, or an alternative currency rate, with margins tied to the Company's Total Leverage Ratio. The credit facility is secured by substantially all of Alnylam's and its material domestic subsidiaries' assets, with guarantees from these subsidiaries. Key financial covenants include maintaining a Total Net Leverage Ratio of no more than 3.75:1.00 (with a potential 0.50:1.00 step-up post-Material Acquisition) and an interest coverage ratio of at least 3.00:1.00. The maturity date could be accelerated under specific conditions related to 'Springing Maturity Debt.' This new credit line provides Alnylam with significant financial flexibility and resources to fund its ongoing operations and strategic initiatives.

Alnylam Pharmaceuticals, Inc. (ALNY) announced the completion of a significant financing event through the issuance of $661.25 million in aggregate principal amount of 0.00% Convertible Senior Notes due 2028. These notes, issued at a substantial premium to the company's stock price, offer flexibility for conversion into Alnylam's common stock under specific conditions, with the company retaining the option to settle conversions in cash, stock, or a combination thereof. The company also strategically entered into capped call transactions, costing approximately $35.3 million, intended to mitigate potential dilution and offset cash outlays associated with note conversions. In conjunction with this offering, Alnylam also repurchased approximately $637.8 million of its existing 1.00% convertible senior notes due 2027 for a total cost of approximately $1,105.8 million. This move indicates a proactive approach to managing its capital structure and debt obligations, potentially reducing future interest expenses and optimizing its financial position. Investors should monitor the conversion rate, potential dilution from stock issuance, and the effectiveness of the capped call strategy.

Alnylam Pharmaceuticals, Inc. (ALNY) announced on September 8th and 9th, 2025, the commencement and subsequent pricing of a proposed offering of convertible senior notes due 2028. This move suggests the company is looking to raise capital through debt financing, which is a common strategy for growth-stage biotechnology firms to fund research, development, and potential commercialization efforts without immediate dilution to existing shareholders. Investors should pay close attention to the terms of these convertible notes, including the principal amount, coupon rate, conversion price, and maturity date, as these will impact the company's future capital structure and potential equity dilution. The offering is being conducted under Rule 144A, targeting qualified institutional buyers, indicating a significant transaction. While the filings do not disclose the exact amount raised, the issuance of convertible notes is a key event that could influence Alnylam's financial flexibility and strategic investments moving forward.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on July 31, 2025, to announce its financial results for the second quarter ended June 30, 2025. The report primarily includes a press release detailing these results. While the specific financial figures are not detailed within the 8-K text itself, investors should refer to the furnished press release (Exhibit 99.1) for comprehensive information regarding the company's performance, revenue, profitability, and any forward-looking guidance provided for the remainder of the fiscal year. This filing serves as the official notification of the company's quarterly performance. Investors are encouraged to review the press release to understand key operational updates, product pipeline progress, and any strategic developments that may have influenced the financial outcomes. The information provided in this 8-K, specifically the financial results, is furnished and not deemed "filed" under Section 18 of the Exchange Act, meaning it does not carry the same legal implications as formally filed information.

Alnylam Pharmaceuticals, Inc. reported a significant increase in total revenues for the six months ended June 30, 2025, up 19% year-over-year to $1.37 billion. This growth was primarily driven by a substantial 47% increase in net product revenues, reaching $1.14 billion, largely attributable to the strong performance of AMVUTTRA, particularly in the treatment of ATTR amyloidosis with cardiomyopathy. ONPATTRO saw a decline in revenue, likely due to patient switching to AMVUTTRA. Conversely, collaboration revenues decreased by 54% to $160.7 million, mainly due to the recognition of a large milestone payment in the prior year's comparable period for the Regeneron collaboration, partially offset by a payment from Vir Biotechnology. Despite revenue growth, the company reported a net loss of $123.8 million for the six months, a widening from the $82.8 million loss in the same period of 2024. This increase in net loss, despite higher revenues, is due to a significant rise in operating costs and expenses, which grew by 19% to $1.37 billion, outpacing revenue growth. The company's balance sheet shows a healthy cash position of $1.11 billion as of June 30, 2025, providing sufficient liquidity for at least the next 12 months. The increase in cash is supported by strong net cash provided by operating activities, which, despite a decrease from the prior year, remains positive at $35.4 million. However, the company continues to incur substantial R&D and SG&A expenses, reflecting ongoing investments in pipeline development and commercialization efforts. The ongoing patent litigation with Moderna and Pfizer remains a notable contingent liability, with recent rulings unfavorable to Alnylam, although the financial impact is not yet quantifiable.

Alnylam Pharmaceuticals, Inc. (ALNY) announced significant organizational changes within its Research and Development (R&D) functions via an 8-K filing on June 18, 2025. The company has combined its Research and Early Development function with its Development function into a single R&D organization to streamline operations and potentially accelerate pipeline progression. This strategic move is accompanied by key leadership adjustments and updated compensation packages for senior R&D executives. Specifically, Dr. Pushkal Garg has been appointed Executive Vice President, Chief Research and Development Officer, consolidating leadership over the newly integrated R&D division. Dr. Kevin Fitzgerald's role has been expanded to include external innovation alongside his existing responsibilities as Chief Scientific Officer. These appointments are supported by revised compensation structures, including salary increases, incentive programs, and a substantial equity grant for Dr. Fitzgerald, signaling the company's investment in and commitment to its top R&D talent as it navigates this organizational shift. Investors should monitor how this R&D integration impacts clinical trial progress and innovation output.

This Form 8-K filing from Alnylam Pharmaceuticals, Inc. details the outcomes of their 2025 Annual Meeting of Stockholders held on May 8, 2025. Key to investors is the stockholder approval and subsequent filing of an amendment to the Company's Certificate of Incorporation to allow for officer exculpation. This change aims to further protect the company's officers from certain liabilities, a common governance enhancement. Additionally, the filing reports on the re-election of four Class III directors, the approval of the Second Amended and Restated 2018 Stock Incentive Plan, and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025. The approval of executive compensation in a non-binding advisory vote also indicates stockholder sentiment on executive remuneration. These outcomes generally reflect stable corporate governance and continued investor confidence in the company's leadership and operational structure. The re-election of directors and approval of incentive plans suggest a continuity in strategy and management oversight. The focus on officer exculpation, while a governance matter, is often viewed positively by management and potentially by investors as it can aid in attracting and retaining qualified leadership by mitigating personal financial risk related to their service. The ratification of the auditor also signals confidence in the company's financial reporting processes.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 1, 2025, announcing its financial results for the quarter ended March 31, 2025. While the 8-K itself primarily serves as a notification of the release and doesn't contain the detailed financial data, it references a press release (Exhibit 99.1) which holds the crucial operational and financial condition information for investors. This filing indicates that key performance metrics, revenue figures, and any significant updates on the company's pipeline or commercial performance for the first quarter of 2025 were disclosed in the accompanying press release.

Alnylam Pharmaceuticals, Inc. reported solid top-line growth for the first quarter of 2025, with total revenues increasing by 20% year-over-year to $594.2 million. This growth was primarily driven by a significant 28% increase in net product revenues, reaching $468.5 million, largely due to strong performance from AMVUTTRA, which saw a 59% increase in total sales across regions. ONPATTRO's sales declined by 29%, attributed to patient switching to AMVUTTRA. While collaboration revenues decreased by 16% mainly due to a large milestone payment received in the prior year from the Roche collaboration, royalty revenue saw a substantial 149% increase, driven by higher royalties from Leqvio. The company narrowed its net loss to $57.5 million from $65.9 million in the prior year's first quarter, indicating progress towards profitability, although significant R&D and SG&A expenses continue to weigh on the bottom line. The company ended the quarter with a robust cash and cash equivalents balance of over $1 billion, providing ample liquidity.

Alnylam Pharmaceuticals, Inc. has announced a significant regulatory milestone with the U.S. Food and Drug Administration's (FDA) approval of its supplemental new drug application for AMVUTTRA® (vutrisiran). This expanded indication allows AMVUTTRA® to treat the cardiomyopathy associated with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adult patients. The approval is specifically for its ability to reduce key cardiovascular outcomes, including mortality, hospitalizations, and urgent visits related to heart failure. This FDA approval represents a major expansion of AMVUTTRA®'s therapeutic reach into a serious and progressive condition where unmet medical needs exist. The drug's demonstrated efficacy in reducing cardiovascular morbidity and mortality in ATTR-CM patients is a crucial development for the company and the patient community. Investors should view this as a positive catalyst, potentially driving significant revenue growth and solidifying Alnylam's position in the rare genetic disease market, particularly in amyloidosis.

Alnylam Pharmaceuticals, Inc. (ALNY) announced on March 5, 2025, that Dr. Phillip A. Sharp will be retiring from the Board of Directors, effective May 8, 2025. This departure is not attributed to any disagreements with the company and is a planned retirement. Dr. Sharp's continued involvement with Alnylam is assured as he will remain a member of the company's Scientific Advisory Board, indicating a smooth transition and ongoing commitment to the company's scientific endeavors.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on February 13, 2025, to announce its financial results for the fourth quarter and full year ended December 31, 2024. While the 8-K itself does not contain the detailed financial figures, it references an accompanying press release (Exhibit 99.1) which will hold the comprehensive performance data and management's commentary. Investors should refer to this press release for specifics on revenue, profitability, and any forward-looking guidance. This filing serves as Alnylam's official notification of its recent financial performance. Key areas of interest for investors will likely include the performance of its commercial products, pipeline advancements, and the company's overall financial health as it moves into the new fiscal year. The press release will provide the critical details to assess Alnylam's execution against its strategic objectives and its potential for future growth.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed its 2024 10-K report, highlighting significant progress in its RNAi therapeutics pipeline and commercialization efforts. The company has five approved products: ONPATTRO, AMVUTTRA, GIVLAARI, OXLUMO, and Leqvio (commercialized by Novartis). A key development is the filing of a supplemental New Drug Application (sNDA) for AMVUTTRA for ATTR amyloidosis with cardiomyopathy, with a target action date from the FDA set for March 23, 2025. The company also reported strong revenue from its TTR franchise, with ONPATTRO and AMVUTTRA generating $252.9 million and $970.5 million in global net product revenues, respectively, for 2024. Furthermore, GIVLAARI and OXLUMO contributed $255.9 million and $167.1 million in global net revenues. Alnylam continues to advance its "Alnylam P5x25" strategy, aiming to become a top-tier biotech company by the end of 2025. The company ended 2024 with a robust cash position of $2.69 billion, indicating financial stability and the ability to fund ongoing operations and development without immediate need for equity financing. The pipeline features several promising late-stage candidates, including zilebesiran for hypertension, nucresiran for ATTR amyloidosis, and mivelsiran for Alzheimer's disease, with significant updates expected in 2025 from clinical trials and regulatory submissions.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report on January 13, 2025, providing preliminary financial results for the fourth quarter and full year 2024, alongside initial guidance for 2025. The company reported approximately $451 million in preliminary fourth-quarter 2024 global net product revenues and $1,646 million for the full year 2024, driven by its key therapies ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. These preliminary figures offer investors an early look at the company's performance ahead of its complete financial results announcement in February 2025. Alnylam has also set forth its product and pipeline goals for 2025, including revenue guidance and non-GAAP operating income guidance, signaling its strategic direction and financial outlook for the upcoming year. Investors should note that these preliminary results are unaudited and subject to adjustments.

Alnylam Pharmaceuticals, Inc. (ALNY) reported a net loss of $111.6 million for the third quarter of 2024, compared to a net income of $147.8 million in the same period last year. This shift is largely due to a significant decrease in collaboration revenues, primarily from the Roche collaboration, which included a substantial upfront payment recognized in Q3 2023. Despite the net loss, product revenues saw robust growth, increasing by 34% year-over-year to $420.1 million, driven by strong performance from AMVUTTRA and growth in GIVLAARI and OXLUMO, partially offset by a decline in ONPATTRO sales. For the nine months ended September 30, 2024, Alnylam reported a net loss of $194.4 million, an improvement from the $302.4 million net loss in the prior year period. Total revenues increased by 19% to $1.66 billion, with net product revenues up 34% to $1.20 billion. However, the company's operating costs and expenses also rose by 11% to $1.73 billion. The company ended the quarter with a strong cash position of $1.10 billion, providing ample liquidity for at least the next 12 months. Management remains focused on advancing its pipeline, with key submissions for AMVUTTRA in cardiomyopathy and positive interim results for mivelsiran in Alzheimer's disease.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on October 31, 2024, to report its financial results for the quarter ended September 30, 2024. The filing includes a press release detailing the company's performance. While specific financial figures are not detailed within the 8-K itself, it serves as the official announcement mechanism for these key results, which are crucial for investors to assess the company's operational and financial health. Investors should refer to the furnished press release (Exhibit 99.1) for a comprehensive understanding of Alnylam's third-quarter 2024 performance, including revenue, profitability, and any updates on their drug pipeline and commercialization efforts. This report signifies a standard disclosure event for publicly traded companies, providing timely information on their ongoing business activities.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 1, 2024, to report its financial results for the second quarter ended June 30, 2024. The key takeaway from this filing is the announcement of these financial results, which were detailed in an accompanying press release furnished as an exhibit. Investors should refer to this press release for specific financial performance metrics, revenue figures, profitability, and any updates on the company's drug pipeline and commercial progress. While the 8-K itself does not contain the detailed financial data, it serves as the official notification of the earnings release. Investors and interested parties are directed to the furnished press release (Exhibit 99.1) for a comprehensive understanding of Alnylam's performance during the second quarter. This typically includes updates on key products, research and development milestones, and forward-looking statements that are crucial for evaluating the company's current standing and future prospects.

Alnylam Pharmaceuticals, Inc. reported robust top-line growth in its second quarter of 2024, with total revenues increasing by 107% year-over-year to $659.8 million. This surge was primarily driven by a significant increase in net product revenues, which rose by 34% to $410.1 million, led by strong performance from AMVUTTRA. Collaboration revenues also saw a substantial increase, growing from $5.8 million in the prior year period to $227.3 million, largely due to the amended collaboration agreement with Regeneron Pharmaceuticals and milestone achievements with Roche. Despite the strong revenue growth, the company reported a net loss of $16.9 million for the quarter, an improvement from the $276.0 million net loss in the second quarter of 2023. This improved net loss reflects the significant increase in revenue and a more favorable cost of goods sold as a percentage of net product revenues. Research and development expenses increased by 18% year-over-year, reflecting ongoing investments in pipeline expansion, particularly for zilebesiran and mivelsiran. The company maintains a strong liquidity position with $971.2 million in cash, cash equivalents, and restricted cash as of June 30, 2024, which management believes is sufficient to meet operating needs for at least the next 12 months.

Alnylam Pharmaceuticals, Inc. (ALNY) held its 2024 Annual Meeting of Stockholders on May 16, 2024, with a filing on May 20, 2024, detailing the outcomes of key votes. The meeting saw the overwhelming re-election of four Class II directors: Dennis A. Ausiello, M.D., Olivier Brandicourt, M.D., Peter N. Kellogg, and David E.I. Pyott, each receiving substantial support from shareholders to serve until the 2027 annual meeting. This demonstrates continued confidence in the board's leadership and strategic direction. Furthermore, Alnylam's stockholders overwhelmingly approved the compensation of the company's named executive officers in a non-binding advisory vote, indicating shareholder alignment with the company's executive compensation policies. The appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2024, was also overwhelmingly ratified, reinforcing the company's commitment to robust financial oversight and transparent reporting. The strong voting results across these critical matters suggest a stable and supportive shareholder base.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 2, 2024, to announce its financial results for the quarter ended March 31, 2024. While the 8-K itself primarily references a furnished press release for the detailed financial information, this filing indicates the company is providing its Q1 2024 operational and financial update to the market. Investors should refer to the press release (Exhibit 99.1) for the specific financial and operational details of the first quarter. This filing serves as the official notification mechanism for the release of this information, highlighting the company's ongoing financial performance and operational status. The information is furnished, not filed, meaning it is provided for disclosure purposes but does not carry the same legal implications under Section 18 of the Exchange Act.

Alnylam Pharmaceuticals, Inc. reported a substantial increase in total revenues for the first quarter of 2024, driven by strong performance in both net product revenues and collaboration revenues. Net product revenues saw a 32% increase year-over-year, primarily fueled by the robust growth of AMVUTTRA, alongside continued strength from GIVLAARI and OXLUMO. Collaboration revenues more than doubled, largely due to revenue recognized from the Roche collaboration, including a significant milestone payment related to the zilebesiran program, and increased activity with Regeneron. Despite the revenue growth, the company reported a net loss of $65.9 million, an improvement from the previous year's loss of $174.1 million, indicating progress in narrowing the operational loss. Research and development expenses increased by 13%, reflecting continued investment in pipeline advancement, particularly for zilebesiran and the HELIOS-B study. Selling, general, and administrative expenses also rose, driven by marketing investments and headcount growth. The company's liquidity remains strong, with cash, cash equivalents, and marketable securities sufficient for at least the next 12 months, according to management.

This 8-K filing from Alnylam Pharmaceuticals, Inc. details the separation of its former Executive Vice President, Chief Legal Officer, and Secretary, Indrani L. Franchini, effective March 1, 2024. The company has entered into a separation and release agreement with Ms. Franchini, outlining the terms of her departure and ongoing engagement as a consultant. This agreement is significant for investors as it clarifies the financial and operational implications of a key executive's exit.

Alnylam Pharmaceuticals, Inc. (ALNY) reported its 2023 financial and operational results, showcasing significant revenue growth driven by its expanding portfolio of RNAi therapeutics. The company's net product revenues reached $1.24 billion, up 39% year-over-year, primarily due to the strong performance of AMVUTTRA and continued growth in GIVLAARI and OXLUMO, partially offset by a decline in ONPATTRO sales as patients transitioned to AMVUTTRA. Collaboration revenues also saw a substantial increase, largely from the new agreement with Roche for zilebesiran and increased royalties from Novartis on Leqvio. Alnylam continues to invest heavily in research and development, with expenses increasing by 14% to $1.0 billion, reflecting progress in its pipeline, including the development of zilebesiran for hypertension and ALN-APP for Alzheimer's disease. The company ended the year with $2.44 billion in cash, cash equivalents, and marketable securities, providing a solid liquidity position. Despite a net loss of $440 million, Alnylam is progressing towards its P5x25 strategic goals, aiming for profitability and a leading biotech profile by the end of 2025.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on February 15, 2024, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2023. The key takeaway for investors is the release of this financial data, which is contained within an attached press release (Exhibit 99.1). This filing serves as the official notification of their latest performance metrics, including revenue, profitability, and potentially forward-looking statements or guidance, though the specifics of these results are detailed in the furnished press release rather than the 8-K itself. Investors should carefully review the accompanying press release for comprehensive details on Alnylam's financial condition and operational results for the period. This includes understanding the company's revenue generation, cost management, and any significant developments impacting their financial outlook. The 8-K filing itself acts as a regulatory gateway to this crucial financial information, highlighting the company's commitment to timely disclosure of material updates.

This 8-K filing from Alnylam Pharmaceuticals, Inc. announces the upcoming departure of its Executive Vice President, Chief Legal Officer, and Secretary, Indrani L. Franchini, effective March 1, 2024. Ms. Franchini will transition from her role, and a formal separation agreement outlining severance and transition terms is expected to be finalized by her Separation Date. Investors should monitor future filings for details on the successor and any impact on the company's legal and corporate governance functions. While this filing primarily pertains to an executive departure, it's important for investors to note that significant leadership changes can sometimes signal shifts in strategy or internal focus. However, the provided details are limited, and no immediate operational or financial impacts are detailed within this specific report. The filing also includes standard exhibit information.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K report announcing preliminary financial results for the fourth quarter and full year 2023. Key takeaways include strong preliminary net product revenues for their key therapies, ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. The company reported approximately $346 million in global net product revenues for Q4 2023 and an impressive $1,241 million for the full year 2023. Furthermore, Alnylam concluded 2023 with a robust cash position, reporting approximately $2.4 billion in cash, cash equivalents, and marketable securities as of December 31, 2023. These preliminary figures provide an early look at the company's performance ahead of their full financial results announcement scheduled for February 2024, indicating positive momentum in revenue generation and a healthy balance sheet.

Alnylam Pharmaceuticals, Inc. (ALNY) has filed an 8-K on November 2, 2023, to report its financial results for the third quarter ended September 30, 2023. While the filing itself does not contain the detailed financial figures, it references a furnished press release (Exhibit 99.1) that provides this information. Investors should refer to this press release for specifics on revenue, profitability, and other key financial metrics. This announcement is crucial for understanding the company's recent performance and its trajectory moving forward. The key takeaway for investors is that Alnylam is providing an update on its financial condition and operational results for the most recent quarter. The 8-K serves as the official notification of this release, directing stakeholders to the accompanying press release for the comprehensive data. It's important to note that the information furnished in this 8-K, including the press release, is not considered "filed" for certain regulatory purposes, which is standard practice for such announcements.

Alnylam Pharmaceuticals, Inc. reported a significant increase in total revenues for the third quarter and first nine months of 2023, driven by strong growth in net product revenues and substantial collaboration revenues, particularly from the new Roche agreement and an early clinical milestone from Regeneron. Net product revenues saw a notable increase of 35% year-over-year in Q3, primarily due to the launch and uptake of AMVUTTRA, offsetting a decline in ONPATTRO sales as patients switched to the newer therapy. The company also reported positive momentum across its other key products, GIVLAARI and OXLUMO. Operationally, the company's focus remains on advancing its pipeline, with significant R&D expenses supporting various clinical programs. Despite an increase in Cost of Goods Sold, largely due to an inventory impairment related to ONPATTRO's ATTR cardiomyopathy indication, the company achieved a net income of $147.8 million in Q3 2023, a significant turnaround from a net loss in the prior year's quarter. This improved profitability reflects the substantial collaboration revenue and disciplined expense management. The company maintains sufficient liquidity and believes its current cash and cash equivalents will support operations for at least the next 12 months.

Alnylam Pharmaceuticals, Inc. (ALNY) announced on October 9, 2023, that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for patisiran. The sNDA sought approval for patisiran, an RNA interference (RNAi) therapeutic, for the treatment of the cardiomyopathy associated with transthyretin-mediated (ATTR) amyloidosis. This development is a setback for Alnylam's efforts to expand the label of patisiran into this significant indication.

Alnylam Pharmaceuticals, Inc. (ALNY) has reported a change in its Board of Directors structure. Marsha H. Fanucci will be resigning from the Board effective September 29, 2023. This departure is explicitly stated as not being due to any disagreements regarding the company's operations, policies, or practices, which suggests a smooth transition. Following Ms. Fanucci's resignation, Peter N. Kellogg is set to assume the role of Chair of the Audit Committee. The Board has confirmed Mr. Kellogg's qualification as an "audit committee financial expert," a key designation for financial oversight. Concurrently, the size of the Board will be reduced from thirteen to twelve members. These changes, while administrative, are important for investors to note regarding board composition and audit committee leadership.

Alnylam Pharmaceuticals, Inc. reported a significant increase in total revenues for the second quarter of 2023, reaching $318.8 million, a 42% increase year-over-year, primarily driven by strong net product revenues. Net product revenues surged by 43% to $305.7 million, largely due to the successful launch and uptake of AMVUTTRA, alongside continued growth from GIVLAARI and OXLUMO. ONPATTRO revenue saw a decline, attributed to patient switches to AMVUTTRA. Collaboration revenues experienced a decrease, mainly due to revised assumptions for the Regeneron collaboration, while royalty revenue from Leqvio significantly increased. Despite revenue growth, the company reported a net loss of $276.0 million for the quarter, reflecting ongoing substantial investments in research and development and selling, general, and administrative expenses. The company's cash position remains robust, providing at least 12 months of operating runway.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on August 3, 2023, primarily announcing its financial results for the quarter ended June 30, 2023. While the 8-K references a press release with these financial details, the filing itself focuses on a significant leadership transition. Akshay K. Vaishnaw, M.D., Ph.D., is transitioning from his role as President to a part-time position as Chief Innovation Officer, effective October 2, 2023. This transition involves specific compensation and severance arrangements detailed in a Letter Agreement. Dr. Vaishnaw will continue with the company in a new capacity, focusing on innovation, while his compensation structure, including base salary and bonus targets, has been adjusted. The agreement also outlines provisions for termination and potential change-in-control scenarios, including continued equity vesting, which investors should note for potential impacts on compensation expenses and leadership continuity.

Alnylam Pharmaceuticals, Inc. (ALNY) has entered into a significant strategic collaboration with Roche Basel and Genentech, Inc. (collectively, Roche) for the joint development and commercialization of zilebesiran, an siRNA therapeutic targeting liver-expressed angiotensinogen (AGT). This agreement grants Roche co-exclusive rights in the United States and exclusive rights outside the U.S. for development and commercialization. This deal provides Alnylam with a substantial upfront payment of $310 million and positions the company to receive up to an additional $2.5 billion in contingent milestone payments. While Alnylam will retain marketing authorization in the U.S. and share profits and losses (50/50) within the U.S., Roche will handle marketing and bear the costs in the Roche Territory, paying Alnylam tiered, low double-digit royalties. This collaboration signifies a key step for Alnylam in advancing zilebesiran, potentially de-risking development and expanding its global reach.

Alnylam Pharmaceuticals, Inc. (ALNY) announced a significant event for its flagship product, ONPATTRO® (patisiran). On June 30, 2023, the company disclosed that the U.S. Food and Drug Administration (FDA) has scheduled a Cardiovascular and Renal Drugs Advisory Committee meeting for September 13, 2023. This meeting will focus on the supplemental New Drug Application (sNDA) for ONPATTRO® seeking approval for the treatment of the cardiomyopathy associated with transthyretin-mediated (ATTR) amyloidosis.

This 8-K filing from Alnylam Pharmaceuticals, Inc. details the outcomes of their Annual Meeting of Stockholders held on May 18, 2023. The key takeaways for investors are the overwhelmingly positive shareholder support for the company's board of directors, executive compensation, and auditor ratification. All proposed director nominees received substantial 'for' votes, indicating shareholder confidence in the current leadership. Furthermore, shareholders approved executive compensation in a non-binding vote and recommended an annual frequency for such votes, aligning with management's intent. The ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2023 also received strong endorsement. These results suggest a stable governance environment and shareholder alignment with the company's strategic direction and financial oversight, which are crucial factors for investor confidence and long-term value creation.

Alnylam Pharmaceuticals, Inc. reported significant top-line growth in the first quarter of 2023, with total revenues increasing by 50% year-over-year to $319.3 million. This growth was driven by a substantial 48% increase in net product revenues, primarily due to the successful launch and uptake of AMVUTTRA in the U.S., alongside continued growth for GIVLAARI and OXLUMO. Collaboration revenues also saw a healthy increase of 41%, largely attributed to enhanced activity with Regeneron Pharmaceuticals. Despite the strong revenue performance, the company continued to operate at a net loss of $174.1 million, though this represents a 28% improvement compared to the same period last year, indicating progress in managing operational costs relative to revenue growth. Operationally, Alnylam is advancing its pipeline with ONPATTRO receiving FDA acceptance for an sNDA for ATTR amyloidosis cardiomyopathy, and AMVUTTRA continuing its global rollout. The company maintains a solid liquidity position with $2.07 billion in cash, cash equivalents, and marketable securities as of March 31, 2023, which it believes is sufficient for at least the next 12 months. While the company continues to invest heavily in R&D, the strong revenue growth suggests a positive trajectory towards its Alnylam P5x25 strategy.

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on May 4, 2023, primarily to report its financial results for the quarter ended March 31, 2023. The key takeaway for investors is the release of these Q1 2023 financial and operational updates, which are detailed in the accompanying press release (Exhibit 99.1). This filing serves as the official channel for disseminating these important performance metrics. While the 8-K itself does not contain the detailed financial figures, it directs investors to the furnished press release for comprehensive information. Investors should review Exhibit 99.1 to understand Alnylam's revenue, earnings, and any significant operational developments or guidance changes announced during the period. It's important to note that the information provided in this 8-K, specifically Item 2.02, is furnished and not deemed "filed" for certain regulatory purposes, meaning it doesn't automatically become part of other SEC filings unless specifically incorporated.